Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Files An 8-K Other EventsItem 8.01. Other Events.
On January16, 2018, the Company issued a press release entitled “Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint.” A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
Item 8.01 Financial Statements and Exhibits.
(d) Exhibits
Eiger BioPharmaceuticals, Inc. ExhibitEX-99.1 2 d527055dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint – End of Phase 2 Meeting Scheduled for HDV in February 2018 – Phase 2 Readouts for PBH and Lymphedema in Second Half 2018 PALO ALTO,…To view the full exhibit click here
About Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)
Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials, which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara, Turkey), LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover, Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema.
